About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Drugs in Baby Trials 'Safe': AIIMS

by Thilaka Ravi on August 27, 2008 at 1:57 PM
Font : A-A+

 Drugs in Baby Trials 'Safe': AIIMS

The All India Institute of Medical Sciences (AIIMS) where 49 babies died in clinical trials conducted at the facility said Tuesday, that the drugs used in the tests were "safe," according to a report.

But the hospital, the state-run All-India Institute of Medical Sciences, said it was conducting an in-house inquiry into the trials, which started in the beginning of 2006 and are ongoing.

Advertisement

"All the studies had undergone scientific scrutiny and had all the required regulatory and ethical approvals," the hospital said in a statement, according to the Press Trust of India news agency.

The institute said the infants died because they had "high-risk and serious disease conditions," the report said.

The hospital denied that the children in the trials came solely from poor families, a concern raised by a non-profit group that had sought information about the trials through a freedom-of-information request.
Advertisement

"There was no question of targeting any socioeconomic group selectively," the hospital statement said.

The hospital said more details would be provided after it completed the inquiry into the trials, which included drugs marketed by the US arm of Swiss-based Novartis and by US-based Shire Human Genetic Therapies.

Some 4,142 babies admitted to the hospital have been in clinical trials since January 1, 2006, more than half of them under the age of one, said the Uday Foundation for Congenital Defects and Rare Blood Groups, which filed the request for information.

The non-profit's founder Rahul Verma said the group hoped to publicise the need for better regulation of India's booming outsourced clinical trial business, estimated at about 120 million dollars last year.

India has become a popular destination for clinical research because of its huge population, varied demographic profile and low costs. Trials here cost 40 to 60 percent of what they would in developed countries.

Consulting firm Ernst & Young has said the outsourced clinical research market in India, which is growing at 25 percent annually, could reach two billion dollars by 2010.

Source: AFP
THK/L
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
News Category
What's New on Medindia
Link between Dietary Intake of Plant-based Essential Fatty Acids and Death Risk
Aspirin may be Harmful When Used for Preventing 1st Heart Attack, Stroke
Pregnancy Complications Elevated Among Symptomatic COVID-19 Women
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Drug Toxicity Signature Drug Toxicity Pregnancy and Antenatal Care Drugs Banned in India Neonatal Abstinence Syndrome 

Recommended Reading
Sudden Infant Death Syndrome / Cot Death
Sudden Infant Death Syndrome is death of a baby, under one year of age that occurs in sleep and ......
Breast Feeding - The Flow - Animation
Interactive section of Medindia explains how the Breast Milk starts to flow...
Drug Toxicity
Drug toxicity is an adverse reaction of the body towards a drug that results as a side effect of a d...
Drugs Banned in India
Several drugs are either banned or withdrawn after introduction in the market....
Neonatal Abstinence Syndrome
Neonatal abstinence syndrome is a condition where newborn babies experience withdrawal symptoms due ...
Pregnancy and Antenatal Care
What is Antenatal care and its importance during pregnancy for mother and baby, with details on the ...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use